Effect of melatonin supplementation in treatment of atopic dermatitis

Phase 3

Conditions: Atopic Dermatitis.
Atopic dermatitis, unspecified
L20.9

Registration Number: IRCT2017082733941N12

Lead Sponsor: Kashan University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 70

Inclusion Criteria

Children diagnosed with atopic dermatitis
Children aged 6-12 years

Exclusion Criteria

Patients who were receiving any systemic corticosteroid or other immunosuppressive drugs or taking antihistamines within the last 3 months before the study
Children diagnosed with acquired immunosuppressive disease
Children diagnosed with other chronic conditions

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
SCORAD index. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: physical exmamination by pediatrician.;Objective SCORAD index. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: physical exmamination by pediatrician.

Secondary Outcome Measures

Name	Time	Method
Pruritus score. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Visual analogue scale 0-10.;Sleep-onset latency. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Children's Sleep Habits Questionnaire.;Total sleep time. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Children's Sleep Habits Questionnaire.;Children's Sleep Habits Questionnaire score. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Children's Sleep Habits Questionnaire.;Serum total IgE levels. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Radioimmunoassay.;High-sensitivity C-reactive protein. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Elisa kit.